Unité Propre de Recherche 9002 du CNRS conventionnée à l'Université Louis Pasteur, IBMC, 15 rue René Descartes, 67084 Strasbourg cedex, France,1 Laboratoire des Fonctions Azotées et Oxygénées Complexes, Unité Mixte de Recherche 6014 du CNRS, IRCOF, Université de Rouen, rue Tesnière, 76821 Mont St. Aignan cedex, France,2 LBPA, Unité Mixte de Recherche 8113 du CNRS, Ecole Normale Supérieure de Cachan, 61 avenue du Président Wilson, 94235 Cachan, France,3 Unité Mixte de Recherche 544 INSERMUniversité Louis Pasteur, Institut de Virologie, 67000 Strasbourg, France4
Received 18 January 2005/ Returned for modification 18 March 2005/ Accepted 13 September 2005
Human immunodeficiency virus type I reverse transcriptase (RT) possesses distinct DNA polymerase and RNase H sites, whereas integrase (IN) uses the same active site to perform 3'-end processing and strand transfer of the proviral DNA. These four enzymatic activities are essential for viral replication and require metal ions. Two Mg2+ ions are present in the RT polymerase site, and one or two Mg2+ ions are required for the catalytic activities of RNase H and IN. We tested the possibility of inhibition of the RT polymerase and RNase H as well as the IN 3'-end processing and transfer activities of purified enzymes by a series of 3,7-dihydroxytropolones designed to target two Mg2+ ions separated by
3.7 Å. The RT polymerase and IN 3' processing and strand transfer activities were inhibited at submicromolar concentrations, while the RNase H activity was inhibited in the low micromolar range. In all cases, the lack of inhibition by tropolones and O-methylated 3,7-dihydroxytropolones was consistent with the active molecules binding the metal ions in the active site. In addition, inhibition of the DNA polymerase activity was shown to depend on the Mg2+ concentration. Furthermore, selective inhibitors were identified for several of the activities tested, leaving some potential for design of improved inhibitors. However, all tested compounds exhibited cellular toxicity that presently limits their applications.
This article has been cited by other articles:
| Clin. Vaccine Immunol. | Clin. Microbiol. Rev. |
|---|---|
| J. Clin. Microbiol. | ALL ASM JOURNALS |